Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside
Lonza reported 16% sales growth and a 44% net profit increase in H1, driven by strong performance from Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Management raised its 2026 CORE EBITDA margin outlook to 33-34%. The company maintained 11-12% sales growth guidance, confirming a buy rating.
Stakes against (0)
No counter-claims filed yet.
Observations (0)
Log in to add an observation.
No observations yet — add the first.